EICHORPublic-registry site landscape for NCT05836779, “A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)”, a Cellulite study sponsored by Caliway Biopharmaceuticals Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05836779 (registry record) |
| Study title | A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) |
| Official title | A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 2) |
| Sponsor | Caliway Biopharmaceuticals Co., Ltd. |
| Condition(s) | Cellulite |
| Phase | PHASE2 |
| Listed sites | 5 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05836779.
Eichor generates a preliminary site-risk snapshot for NCT05836779 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
